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Methodology 
This Good Practice Paper was compiled according to the BSH process at 
http://www.b-s-h.org.uk/guidelines/proposing-and-writing-a-new-bsh-guideline/. The 
British Society for Haematology (BSH) produces Good Practice Papers to 
recommend good practice in areas where there is a limited evidence base but for 
which a degree of consensus or uniformity is likely to be beneficial to patient care. 
The Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) nomenclature was used to evaluate levels of evidence and to assess the 
strength of recommendations. The GRADE criteria can be found at 
http://www.gradeworkinggroup.org. 
 
Literature review details 
A search for English language literature on glucocorticoid-induced osteoporosis in 
patients with immune thrombocytopenia (ITP) from 1960 to 2017 was carried out on 
the 21st November 2017.   Ovid Medline, Embase and the Cochrane database of 
systematic reviews were searched.  Details of the search and a summary table of the 
main findings can be found in Supplementary Appendix 1. 
 
Review of the manuscript 
Review of the manuscript was performed by members of the UK ITP Forum, the 
Committee of Scientific Advisors of the International Osteoporosis Foundation, the 
British Society for Haematology (BSH) Guidelines Committee General Haematology 
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Task Force, the BSH Guidelines Committee and the General Haematology Sounding 
Board of BSH. It was also on the members section of the BSH website for comment. 
It has also been reviewed by The ITP Support Association, although this 
organisation does not necessarily approve or endorse the contents. 
 
Introduction 
Glucocorticoids are a standard first line treatment for immune thrombocytopenia 
(ITP) and are an important risk factor for osteoporosis.  Glucocorticoids act directly to 
suppress bone formation by inhibiting osteoblast function and triggering osteoblast 
(and osteocyte) apoptosis.  They also act indirectly by inhibiting intestinal calcium 
absorption and reducing gonadal hormones.  Despite this, current ITP guidelines (3, 
4) have not addressed the need to identify patients at high risk of fragility fracture, 
who would benefit from bone-protective treatment.  However, recent guidelines for 
the prevention and treatment of osteoporosis give recommendations for patients 
receiving glucocorticoids, irrespective of underlying diagnosis (1, 5) and have been 
based on systematic review of the literature.  In this good practice paper, we conduct 
a systematic review of the literature on osteoporosis in patients with ITP receiving 
glucocorticoids, assess the applicability of current guidelines on prevention of 
glucocorticoid-induced osteoporosis (GIOP) to the treatment regimens used for 
patients with ITP and make treatment recommendations. 
 
Prevention of osteoporosis in patients receiving glucocorticoids  
Fragility fractures, particularly vertebral fractures, occur in up to 30-50% of adults 
receiving long term glucocorticoids (6).  Loss of bone mineral density (BMD) is most 
rapid in the first 3-6 months but continues to decline at a slower rate with continued 
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use (5).  This is associated with an increased fracture risk, and a meta-regression 
analysis of randomised controlled trials found that the annual incidence of vertebral 
fracture was 5.1% in patients who had commenced glucocorticoids ≤6 months 
previously vs. 3.2% if commenced >6 months ago (7).  Loss of BMD appears 
partially reversible after withdrawal of glucocorticoids and withdrawal leads to a 
reduction in fracture risk (6) although a residual increased risk persists (8). Fracture 
in patients receiving glucocorticoids is not solely dependent on bone loss (8) and 
fractures occur at higher BMD compared to postmenopausal osteoporosis (9).  
Fracture risk rises with age, and with higher cumulative and daily dose of 
glucocorticoids.  Additional clinical risk factors for fracture that are independent of 
BMD are listed in table 1 (1).  A UK evidence based guideline for osteoporosis 
prevention has recently been published (1).  The guideline considers patients 
receiving glucocorticoids with an anticipated duration of ≥3 months and some key 
conclusions are summarised in table 2, although clinicians should refer to the original 
guideline for full details. The input of an endocrinologist may be helpful for complex 
cases.    
 
Fracture risk assessment 
The management of children and adults <40 was not addressed in detail in the UK 
osteoporosis guideline.  Although fracture risk is lower in pre-menopausal women 
and men <50, this risk can still be significant in some individuals, for example the 10-
year fracture risk has been estimated at 5–20% in pre-menopausal women ≥30 
years receiving very high doses of glucocorticoids (5).  Other risk factors identified in 
pre-menopausal women include prior fragility fracture, low BMD, family history of 
osteoporosis, low body mass index or low weight, age, age at menarche, major 
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depression and alcohol intake (11, 14-18).  Recent American guidelines concluded 
that BMD testing should be considered in adults age <40 at treatment onset if there 
were additional risk factors, and bone protective therapy considered in adults <40 if 
1) prior fragility fracture 2) receiving ≥7.5 mg prednisolone daily with a Z score < -3 at 
hip or spine or 10% or more BMD loss/year at hip or spine 3) age ≥30 receiving ≥30 
mg prednisolone daily with a cumulative dose >5g in the last year (5).    
 
For patients age 40-90 years, clinical risk factors (with or without a BMD 
measurement) can be entered into a validated algorithm (FRAX®), available on line 
at www.sheffield.ac.uk/FRAX/tool.jsp that calculates the 10 year probability of hip 
fracture or major osteoporotic fracture (i.e. clinical fracture at the spine, distal 
forearm, humerus or hip). Having calculated the fracture risk on-line, a link is 
provided to guidance from the National Osteoporosis Guideline Group (NOGG) 
based on UK intervention thresholds for treatment, that is adjusted for steroid dose 
(for patients outside the UK, adjustments to FRAX risk based on age and steroid 
dose can be found in Supplementary Appendix 2).  High risk patients should be 
considered for bone-protective treatment such as an oral bisphosphonate.  Patients 
at low risk can be reassured and provided with lifestyle advice.  BMD assessment is 
recommended for those with intermediate risk and the result entered into the FRAX 
tool to determine the need for treatment. 
 
Because the intervention threshold is generally exceeded, bone protective treatment 
can be considered in 1) men or women ≥70 years, and 2) men ≥50 or post-
menopausal women with a prior fragility fracture or taking a high dose of 
glucocorticoids (≥7.5 mg prednisolone), without further risk assessment (1). 
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Interventions 
Interventions for patients at risk of GIOP include lifestyle measures, optimizing 
calcium and vitamin D intake, and bone protective therapies.  The evidence base for 
lifestyle measures in adults (Table 2) is based on smoking and greater alcohol intake 
being risk factors for osteoporosis (22, 23) and weight-bearing exercise having a 
beneficial effect on BMD (24), rather than evidence that these measures will prevent 
fractures.  Two meta-analysis found that for patients receiving glucocorticoids, the 
combination of calcium and vitamin D supplements was more effective in preserving 
BMD than calcium alone or no therapy (25, 26).  Bisphosphonates (e.g. alendronate, 
risedronate or zoledronic acid) and teriparatide (recombinant human parathyroid 
hormone) have been shown to reduce fractures in post-menopausal women with 
osteoporosis (27-30).  They are also licenced for the prevention of GIOP, with 
evidence of effectiveness in BMD bridging studies (31-34) and subsequently, 
fracture prevention (19-21).  Treatment has also been shown to preserve bone 
density in pre-menopausal women while data in men age <50 years is limited (11). 
 
Good prescribing practice 
Bisphosphonates have a number of contra-indications such as hypocalcaemia, 
hypersensitivity, severe renal impairment, pregnancy and lactation. Oral 
bisphosphonates should be avoided in those unable to stand or sit upright for at least 
30-60 minutes and those with oesophageal stricture or achalasia.  Rare adverse 
events include osteonecrosis (jaw or external auditory canal) and atypical femoral 
fractures.  Patients should be encouraged to have a pre-treatment dental review, 
maintain good oral hygiene, avoid dental intervention if possible while on treatment, 
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and to report dental problems, recurrent ear infections and hip, thigh or groin pain 
(1).  There is inadequate safety data for the use of bisphosphonates in pregnancy 
and given their long half-life, these should be avoided in women of child bearing 
potential unless there is a strong indication for treatment (11).   
 
Impact of glucocorticoids in patients with ITP 
Our systematic review identified four case series or case-control studies of between 
24 and 36 children and one adult series of 18 patients assessing bone mineral 
density (BMD) after steroids (Supplementary appendix 1).  In children, there was a 
significant negative correlation between BMD and cumulative steroid dose (35-37).  
In one series, 9/36 (25%) children had osteopenia and one had osteoporosis (36).  
BMD was significantly lower in children receiving a cumulative dose over 2100 mg/kg 
compared with those receiving less (35) and a BMD Z-score of less than -2 standard 
deviations was found in 5/9 children receiving a cumulative dose >1000 mg/kg vs. 
0/19 receiving a cumulative dose <1000 mg/kg (37).  Different regimens appeared to 
vary in their impact on BMD but data were insufficient to draw conclusions.  In the 
adult study, the average total (prednisolone equivalent) dose received was 5233 ± 
3541 mg.  7/18 (39%) patients had osteoporosis and a significant negative 
correlation was found between BMD and both total, and mean daily, steroid dose 
(38).  The same study reported on BMD in 32 patients with low bone mass, before 
and after treatment with the bisphosphonate alendronate, finding a significant 
increase after 6 and 12 months.  
 
There is no mechanistic reason to think that the impact of glucocorticoids on bone 
mineral density, or the effects of treatment to prevent osteoporosis should be 
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different in patients with ITP, as compared to patients with other disorders.  The 
studies reviewed support this. 
 
Recommendation: general guidelines for osteoporosis prevention are 
applicable to patients with ITP (1C).  
 
Do the glucocorticoid dosing regimens used in ITP impact on the application 
of osteoporosis guidelines? 
Although an arbitrary cut off, some studies have found that fracture risk is not 
significantly elevated in patients receiving steroids for <3 months (10) and most 
guidelines are for patients with an intended duration of treatment ≥3 months (5, 11). 
These guidelines have recognised a daily dose of ≥ 5-7.5 mg oral prednisolone or 
equivalent as high risk.  Research from the United Kingdom GP database found that 
patients aged ≥40 years receiving high dose intermittent oral glucocorticoids (defined 
as at least one prescribed daily dose ≥15 mg) but for a short duration (cumulative 
dose ≤1 g) had only a small increase in the risk of fracture.  Risk was substantially 
increased when the daily dose was ≥15 mg and cumulative dose >1 g.  The highest 
vertebral fracture risk (relative risk 14.4) was with a daily dose ≥30 mg and 
cumulative dose >5 g (12). A second population based study also found that in 
patients aged ≥18 receiving a cumulative dose <1 g, the risk of major osteoporotic 
fracture was not increased (13). 
 
Adults 
Glucocorticoids are currently a first line treatment for ITP but relapsing patients may 
receive repeated courses, either as rescue therapy, in combination with other 
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treatments, or as low dose maintenance therapy in selected refractory cases (2-4, 
39).  Newer therapeutic agents for ITP such as thrombopoietin receptor agonists 
(TPO-RA) have reduced but not eliminated the need for longer term glucocorticoids 
and in an open label extension study of the TPO-RA romiplostim, glucocorticoids 
were required in 35% of patients during weeks 1–24, and 20% during weeks 121–
144 (40). 
 
Initial treatment is with oral prednisolone 1 mg/kg for between 4 days and 4 weeks 
followed by a taper over 4-6 weeks (2-4, 41), or with dexamethasone 40 mg daily for 
4 days every 2-4 weeks for 1-4 cycles (4, 41).  The cumulative steroid dose for 
typical first line adult regimens is therefore approximately 1-2 g (Table 3).  Hence the 
daily and cumulative doses are high, but the duration is slightly shorter than covered 
by standard guidelines for glucocorticoid-induced osteoporosis.   
 
Children 
In children requiring treatment of their ITP, steroids are often used first line.  
However paediatric regimens are usually shorter, for example  prednisolone 3-4 
mg/kg/day for 4 days, or prednisolone 2 mg/kg for 14 days then stopped or tapered 
over a further 21 days (3, 4) (Table 3).  As shown above, some children 
subsequently receive multiple glucocorticoid courses that result in reduced BMD. 
  
 
The recommendations below are based on recent UK NOGG guidelines for the 
prevention and treatment of osteoporosis (1), which are accredited by the National 
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Institute of Health and Care Excellence (NICE).  However, they have been further 
adapted to consider the typical dose and duration of steroids used for ITP patients. 
 
Recommendations  
 
Initial fracture risk assessment 
• Patients age ≥70 years, or men ≥50 years and post-menopausal women 
with a previous fragility fracture can be considered high risk and not 
require further assessment (Figure 1) (2C) 
• At treatment onset, patients age 40-69 (excluding men ≥50 years and 
post-menopausal women with previous fragility fracture) should be 
assessed by FRAX score without BMD assessment at treatment onset 
(www.sheffield.ac.uk/FRAX/tool.jsp) to define high, intermediate or low 
risk (2C).   
• Ideally, those at intermediate risk should have a DXA (dual energy x-ray 
absorptiometry) scan and femoral neck BMD entered into FRAX to 
define high and low risk.  However in patients receiving a short steroid 
regimen i.e. ≤12 weeks, particularly when a DXA result is unlikely to be 
available during treatment, a decision can be made clinically and not all 
patients require bone-protective treatment (2C). 
• Adults age <40 years and children do not routinely require DXA 
assessment (2C). 
 
Interventions 
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• All adults starting on glucocorticoids should be given lifestyle advice to 
optimise bone health (Table 2) (2C). 
• Check serum calcium and vitamin D levels (2C) 
• Adequate daily vitamin D (800 iu) and calcium (700-1200 mg) intake in 
adults is recommended through diet if possible or supplements if 
needed, but with a relatively short anticipated duration of treatment, 
supplements may be the most practical method of ensuring adequate 
intake (2C). 
• Patients at high risk of fracture should be considered for an oral 
bisphosphonate such as alendronate or risedronate.  If contraindicated 
or poorly tolerated, zoledronic acid or teriparatide are appropriate 
alternatives (1A). 
 
Patients receiving similar glucocorticoid regimens for relapse 
• Use the minimum necessary dose and consider whether glucocorticoid 
sparing alternatives are appropriate (2C) 
• Patients previously treated with bisphosphonates may be re-treated 
(Figure 2) (2C). 
• If re-treatment with glucocorticoids is within a year, men over 50 and 
post-menopausal women may be considered high risk.  Other adults ≥40 
years should be risk assessed (2C) 
• Use of bisphosphonates may be appropriate in selected adults <40 
years and children, particularly those with a prior fragility fracture or 
receiving high cumulative doses e.g. ≥1 g/kg in children or ≥5g in adults.    
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Measurement of BMD may be helpful in assessment of risk and to 
monitor the effects of treatment (2C)  
 
Discontinuing bisphosphonates 
• When a patient stops their glucocorticoid, the bisphosphonate can also 
be stopped following an individual risk assessment.  This may include 
assessment of BMD in patients who have received prolonged therapy 
(2C) 
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Clinical risk factors for fracture independent 
of BMD and age 
Low body mass index (≤19 kg/m2) 
Previous fragility fracture (e.g. hip, vertebral) 
Parental (mother or father) history of hip fracture 
Current smoking 
Alcohol intake ≥3 units/day 
Rheumatoid arthritis 
Glucocorticoid therapy 
 
 
 
 
 
 
 
 
 
  
Table 1. Clinical risk factors for fracture 
BMD; bone mineral density 
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Fracture risk assessment in patients receiving glucocorticoids 
 • Consider bone-protective therapy in men or women ≥70 years, those with a prior fragility 
fracture and those taking a high dose of glucocorticoids (≥7.5 mg prednisolone). 
 • In other individuals, fracture probability should be estimated using FRAX with adjustment 
for glucocorticoid dose. 
Lifestyle and dietary advice 
 • Adults should receive lifestyle advice (regular weight-bearing exercise, stop smoking, 
reduce alcohol intake to ≤2 units/day)  
 • Adults should receive adequate daily intake of calcium (700-1200 mg) and vitamin D 
(800 iu) through diet if possible or supplements if needed 
Bone-protective therapy 
 • Because bone loss and increased fracture risk occur early after initiation of 
glucocorticoids, bone-protective treatment should be started at the onset of therapy in 
patients at increased risk of fracture 
 • Bone-protective therapy may be appropriate in some premenopausal women and 
younger men, particularly in individuals with a previous history of fracture or receiving 
high doses. 
 • For adults at high risk of fracture, consider an oral bisphosphonate such as alendronate 
or risedronate.  If contraindicated or poorly tolerated, zoledronic acid or teriparatide are 
appropriate alternatives 
 • On stopping glucocorticoids, consider stopping bone-protective therapy following an 
individual risk assessment.  This may include assessment of BMD in patients who have 
received prolonged therapy 
 
 
 
 
 
  
Table 2.  Summary of recent guidance on the assessment of fracture risk and indications for 
treatment in men ≥50 and post-menopausal women receiving glucocorticoids for ≥3 months 
(1)  
BMD; bone mineral density 
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Glucocorticoid regimen Cumulative (prednisolone 
equivalent) steroid dose 
Prednisolone 1 mg/kg for 21 days then tapered (70 
kg) 
2520 mg 
Prednisolone 1 mg/kg for 4 days then tapered (70 
kg) 
1330 mg 
Dexamethasone 2 cycles of 40 mg daily for 4 days 2133 mg 
Prednisolone 4 mg/kg/day for 4 days (30 kg) 480 mg (16 mg/kg) 
Prednisolone: 7.5 mg daily for 3 months (84 days) 630 mg 
 
 
 
 
 
 
 
  
Table 3. Cumulative steroid dose for typical first line ITP steroid regimens 
compared with threshold duration and dose considered high risk 
(prednisolone ≥7.5 mg daily for ≥3 months) 
For doses in mg/kg, weight used for estimate of cumulative steroid dose is in 
brackets. 
Steroid taper: prednisolone 40 mg daily for 2 weeks, 20 mg daily for 2 weeks, 10 
mg daily for 2 weeks, 5 mg daily for 2 weeks then stop (2) 
Dexamethasone was converted to prednisolone at a ratio of 0.75 mg to 5 mg 
(Mager 03) 
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Figure 1. Risk adapted approach to bisphosphonate treatment for patients with ITP 
receiving first line glucocorticoids 
ITP; immune thrombocytopenia, DXA; dual energy x-ray absorptiometry  
*FRAX is a fracture risk assessment tool www.sheffield.ac.uk/FRAX/tool.jsp 
†Local access to DXA may vary.  If a report will not be available during glucocorticoid 
treatment, a decision should be made on clinical grounds in patients with intermediate 
risk FRAX.   
Children and adults 
age <40 
Adults ≥40 years 
Treatment not 
routinely required 
Treatment not 
required 
Consider treatment 
Low risk High risk 
Intermediate risk 
DXA scan† 
Age ≥70 years or men ≥50 
years and post-menopausal 
women with prior 
insufficiency fracture 
Consider treatment FRAX* assessment 
No Yes 
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Figure 2. Risk adapted approach to bisphosphonate treatment for patients with ITP 
receiving retreatment with glucocorticoids 
ITP; immune thrombocytopenia, DXA; dual energy x-ray absorptiometry  
*FRAX is a fracture risk assessment tool www.sheffield.ac.uk/FRAX/tool.jsp 
Children and adults 
age <40 
Clinical 
assessment. 
In selected cases, 
DXA scan may be 
helpful for risk 
assessment and 
treatment may 
sometimes be 
appropriate 
Adults ≥40 years 
Previous treatment 
Consider re-
treatment 
Men age ≥50 years 
or post-menopausal 
women.  Re-treated 
in ≤1 year 
No Yes 
FRAX* re-
assessment 
No Yes 
Consider treatment 
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